Risk factors

Smart Sand depends heavily on oil and gas industry activity, customer concentration, rail transport, and mining regulations.

Instil Bio faces high financial losses, having accumulated $655.1 million in deficit as of December 31, 2024. The company relies heavily on its collaboration with ImmuneOnco for its lead product candidates AXN-2510/IMM2510 and AXN-27M/IMM27M. It has zero commercial products and no history of completing clinical trials.

Business depends heavily on oil and gas prices, production declines, and borrowing capacity under its credit facility.

UNL tracks a 12-month natural gas futures benchmark tied to Henry Hub prices.

This initial filing details operational concentration in the Gulf of America, significant long-term debt and surety collateral demands, and heavy regulatory and environmental compliance burdens.

Clinical-stage biotechnology company developing RNA medicines via the PRISM platform with recurring operating losses. Extensive reliance on external funding, third-party collaborations, and complex oligonucleotide manufacturing.

Pepsi accounted for 54.7% of 2024 net revenue and 62.2% of year-end receivables, creating major customer concentration.

Premier Financial merger execution, integration costs and potential liabilities dominate the company-specific risks.

Advanced Products revenue depends heavily on one or a few customers.

Insurance profitability depends on accurate pricing, reserves, claims handling, catastrophe forecasting, and affordable reinsurance.

Accel faces extensive regulation across multiple jurisdictions and relies heavily on key location contracts and equipment manufacturers. The December 2024 Fairmount acquisition expands the business into new casino and horse racing operations with distinct risks. Substantial indebtedness of $597.4 million requires significant cash flows for debt service and limits operating flexibility.

Substantially all operations and sales are concentrated in mainland China and Asia, exposing the company to geopolitical, regulatory, and trade risks. U.S. and allied export controls restrict the company's ability to procure controlled items and sell tools to certain Chinese customers. The business relies heavily on a small group of major chipmaker customers and is vulnerable to semiconductor industry cyclicality. The company depends on third-party suppliers and single-source vendors for critical tool components and subassemblies.